암닐 파마슈티컬스(Amneal Pharmaceuticals, Inc.)
US ˙ NasdaqGS ˙ US03168L1052

SecurityAMRX / Amneal Pharmaceuticals, Inc.
InstitutionAperio Group, LLC
Latest Disclosed Ownership89,637 shares
Latest Disclosed Value $ 410,000
Aperio Group, LLC reports 9.39% increase in ownership of AMRX / Amneal Pharmaceuticals, Inc.

On February 5, 2021 - Aperio Group, LLC filed a 13F-HR form disclosing ownership of 89,637 shares of Amneal Pharmaceuticals, Inc. (US:AMRX) valued at $409,641 USD as of December 31, 2020. The entity filed a previous 13F-HR on November 6, 2020 disclosing 81,940 shares of Amneal Pharmaceuticals, Inc.. This represents a change in shares of 9.39% during the quarter. The current value of the position is $1,232,509 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2021-02-05 2020-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 89,637 7,697 9.39 410 28.93 0.0012
2020-11-06 2020-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 81,940 -3,485 -4.08 318 -21.87 0.0011
2020-08-13 2020-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 85,425 -1,087 -1.26 407 35.22 0.0015
2020-05-05 2020-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 86,512 56,569 188.92 301 109.03 0.0013
2020-02-13 2019-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 29,943 5,527 22.64 144 102.82 0.0005
2019-11-06 2019-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 24,416 12,083 97.97 71 -19.32 0.0003
2019-07-30 2019-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 12,333 -7,330 -37.28 88 -68.46 0.0004
2019-05-13 2019-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 19,663 -15,648 -44.31 279 -41.63 0.0012
2019-05-06 2018-12-31 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 35,311 -5,964 -14.45 478 -47.82 0.0024
2019-02-14 2018-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 35,311 478
2019-05-06 2018-09-30 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 41,275 -1,967 -4.55 916 29.20 0.0040
2018-10-17 2018-09-30 13F AMNEAL PHARMACEUTICAL COMMON 03168L105 41,275 916
2019-05-06 2018-06-30 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A ADDED 03168L105 43,242 43,242 709 0.0034
2018-07-30 2018-06-30 13F AMNEAL PHARMACEUTICAL COMMON 03168L105 43,242 710
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.